相关实验视频

Updated: Sep 13, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

CD20CAR-T疗法预防性治疗CD19CAR-T治疗后在部分缓解中复发/逆转DLBCL的患者

Fei Xue¹, Huazhou Shi², Rui Liu¹

¹Department of Lymphoma and Myeloma Research Center, Beijing Gobroad Boren Hospital, Beijing, China.

Transplantation and cellular therapy

|August 1, 2025

概括

在CD19CAR-T部分缓解后与CD20仿真抗原受体T细胞 (CD20CAR-T) 疗法结合,显著改善了扩散大B细胞淋巴瘤患者的结果. 这种方法提供了一个有前途的策略,以防止疾病的进展.

科学领域:

血液学血液学血液学
免疫治疗是一种免疫疗法.
在瘤学瘤学.

背景情况:

复发或不耐药的扩散性大B细胞淋巴瘤 (r/rDLBCL) 患者在CD19仿真抗原受体T细胞 (CD19CAR-T) 治疗后实现部分缓解 (PR) 后有很高的进展风险.
新的整合策略对于改善这一具有挑战性的患者群体的结果至关重要.

研究的目的:

评估CD20CAR-T疗法的有效性,作为在r/r DLBCL患者的预防性整合策略,在CD19CAR-T疗法后实现PR.
评估与连续CD19CAR-T和CD20CAR-T治疗相关的安全性和生存结果.

主要方法:

在北京戈布罗德博伦医院 (2019-2022) 用连续的CAR-T疗法治疗r/rDLBCL的成年患者的回顾性分析.
收录标准:在CD19CAR-T之后取得PR,随后获得CD20CAR-T.
19名患者符合分析的资格标准.

主要成果:

在CD20CAR-T整合后,19名患者中有16名 (84.2%) 实现了完全缓解 (CR).
无进展生存 (PFS) 的中位数为27.0个月 (95% CI,14.6-NR),随访时间的中位数为29.4个月.
总生存时间 (OS) 的中位数没有达到;没有观察到严重的 (等级≥3) 细胞因子释放综合征 (CRS) 或免疫效应细胞相关的神经毒性综合征 (ICANS).

结论:

CD20CAR-T疗法显示出显著的前景,作为CD19CAR-T后的PR中r/rDLBCL患者的预防性整合策略.
这种顺序的CAR-T方法似乎是安全有效的,可以加深缓解并延长存活时间.
进一步的前性研究是有必要的,以在更大的队列中证实这些发现.

关键词:

在B细胞淋巴瘤.在CD20CAR-T中.整合疗法是一种整合疗法.DLBCL DLBCL 是一个字母.持久的缓解持续缓解.

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.